ClinicalTrials.gg

Program

Cetuximab

Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Neoplasms, led by 26 companies.

Furthest: phase 3, since Jun 4, 200390 company-led studies, 13 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly300 open or runningphase 3since Jun 4, 2003Apr 30, 2002none ahead
Merck KGaA, Darmstadt, Germany170 open or runningphase 3since Sep 7, 2005Jul 28, 2005none ahead
Pfizer53 open or runningphase 3since Oct 5, 2020Dec 1, 2010Dec 31, 2029phase 2 · NCT05226871
Bristol-Myers Squibb40 open or runningphase 3since Nov 17, 2017Jan 7, 2008none ahead
Hoffmann-La Roche41 open or runningphase 2since Dec 18, 2007Jul 3, 2007Aug 31, 2030phase 1 · NCT04929223
R-Pharm40 open or runningphase 3since Feb 20, 2026Sep 28, 2006none ahead
Sarah Cannon Research Institute41 open or runningphase 3since Nov 9, 2005Nov 2, 2005none ahead
Merck22 open or runningphase 3since May 21, 2025May 21, 2025Mar 28, 2029phase 3 · NCT06997497
Novartis20 open or runningphase 2since May 16, 2012May 24, 2007none ahead
Pierre Fabre20 open or runningphase 2since Sep 17, 2018Sep 17, 2018none ahead
Bayer10 open or runningphase 1since Oct 28, 2013Oct 28, 2013none ahead
BOE Technology Group11 open or runningphase 2since Apr 10, 2026Apr 10, 2026Apr 2028phase 2 · NCT07551778
Boehringer Ingelheim10 open or runningphase 1since Dec 19, 2013Dec 19, 2013none ahead
boneca-corporation10 open or runningphase 2since Jun 21, 2009Jun 21, 2009none ahead
cinnagen11 open or runningphase 3since Dec 31, 2017Dec 31, 2017none ahead
Daiichi Sankyo10 open or runningphase 1since Jan 19, 2015Jan 19, 2015none ahead
Fosun Pharma11 open or runningphase 1since Apr 7, 2026Apr 7, 2026Jun 30, 2027phase 1 · NCT07543471
GlaxoSmithKline10 open or runningphase 1since Oct 5, 2007Oct 5, 2007none ahead
Haisco Pharmaceutical Group11 open or runningphase 2since Aug 13, 2026Aug 13, 2026Sep 30, 2029phase 2 · NCT07790510
harrison-clinical-research10 open or runningphase 1since Jan 9, 2009Jan 9, 2009none ahead
innate-pharma10 open or runningphase 2since Dec 17, 2015Dec 17, 2015none ahead
integragen-sa10 open or runningphase 3since Nov 24, 2017Nov 24, 2017none ahead
Merrimack Pharmaceuticals10 open or runningphase 1since Oct 7, 2011Oct 7, 2011none ahead
Revolution Medicines11 open or runningphase 2since May 20, 2024May 20, 2024Sep 30, 2028phase 2 · NCT06445062
shanghai-celfuture-biotech-co-ltd10 open or runningphase 2since Jan 4, 2023Jan 4, 2023none ahead
Verastem11 open or runningphase 2since Jun 15, 2026Jun 15, 2026Jun 2027phase 2 · NCT07659795

Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, prologue-research-international, Sanofi and merck-s-l-spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jul 3, 2007.

  1. Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
  2. Apr 30, 2021Phase 2 study in Colorectal NeoplasmsPierre Fabre · NCT05004350 · 107 enrolled · China
  3. Jun 11, 2021Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT04929223 · 542 planned · United States, Australia, Canada and more
  4. Jan 19, 20222 phase 2 studiesPfizer · NCT05217446, NCT05226871
  5. Jan 4, 2023shanghai-celfuture-biotech-co-ltd's first study: phase 2 study in Colorectal NeoplasmsNew to shanghai-celfuture-biotech-co-ltdshanghai-celfuture-biotech-co-ltd · NCT05684211 · 84 enrolled · China
  6. May 20, 2024Revolution Medicines's first study: phase 2 study in Colorectal NeoplasmsNew to Revolution MedicinesRevolution Medicines · NCT06445062 · 1,130 planned · United States
  7. May 21, 2025Merck's first study: phase 3 study in Colonic NeoplasmsNew to MerckMerck · NCT06997497 · 477 planned · United States, Argentina, Australia and more
  8. Nov 20, 2025Phase 2 study in NeoplasmsMerck · NCT07252739 · 140 planned · United States, Chile, China and more
  9. Feb 20, 2026Phase 3 study in Squamous Cell Carcinoma of Head and NeckPhase 3 reachedR-Pharm · NCT07435324 · 161 enrolled · Russia, Uzbekistan
  10. Feb 20, 2026Phase 1 study in Squamous Cell Carcinoma of Head and NeckR-Pharm · NCT07435311 · 118 enrolled · Russia
  11. Apr 7, 2026Fosun Pharma's first study: phase 1 study in mCRCNew to Fosun PharmaFosun Pharma · NCT07543471 · 387 planned
  12. Apr 10, 2026BOE Technology Group's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to BOE Technology GroupBOE Technology Group · NCT07551778 · 42 planned
  13. Jun 15, 2026Verastem's first study: phase 2 study in Colorectal NeoplasmsNew to VerastemVerastem · NCT07659795 · 150 planned · United States, Australia
  14. Aug 13, 2026Haisco Pharmaceutical Group's first study: phase 2 study in Colorectal NeoplasmsNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07790510 · 180 planned · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsVerastem · NCT07659795
  2. Jun 30, 2027Primary completion: phase 1 study in mCRCFosun Pharma · NCT07543471
  3. Apr 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBOE Technology Group · NCT07551778
  4. Sep 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsRevolution Medicines · NCT06445062

TargetBeta

EGFR →read by rule
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

The newest 60 of 90 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07790510Colorectal Neoplasms · China2RecruitingHaisco Pharmaceutical GroupSep 30, 2029180
NCT07659795Colorectal Neoplasms · United States, Australia2RecruitingVerastemJun 2027150
NCT07551778Carcinoma, Non-Small-Cell Lung2Not yet recruitingBOE Technology GroupApr 202842
NCT07543471mCRC1Not yet recruitingFosun PharmaJun 30, 2027387
NCT07435324Squamous Cell Carcinoma of Head and Neck · Russia, Uzbekistan3CompletedR-PharmSep 16, 2025161
NCT07435311Squamous Cell Carcinoma of Head and Neck · Russia1CompletedR-PharmJul 17, 2024118
NCT07252739Neoplasms · United States, Chile, China and more2RecruitingMerckNov 15, 2029140
NCT06997497Colonic Neoplasms · United States, Argentina, Australia and more3RecruitingMerckMar 28, 2029477
NCT06445062Colorectal Neoplasms · United States2RecruitingRevolution MedicinesSep 30, 20281,130
NCT05684211Colorectal Neoplasms · China2UNKNOWNshanghai-celfuture-biotech-co-ltdJan 202384
NCT05226871Breast Neoplasms · United States, China, Mexico and more2Active, not recruitingPfizerDec 31, 202935
NCT05217446Colorectal Neoplasms · United States, Australia, Belgium and more2Active, not recruitingPfizerJun 19, 2026108
NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more1RecruitingHoffmann-La RocheAug 31, 2030542
NCT05004350Colorectal Neoplasms · China2CompletedPierre FabreDec 19, 2023107
NCT04607421Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerMar 1, 2025841
NCT04515394Colorectal Neoplasms · United States, Belgium, Czechia and more2TerminatedMerck KGaA, Darmstadt, GermanyMar 14, 20223
NCT03717155Carcinoma, Non-Small-Cell Lung · Hungary, Serbia, Spain2CompletedMerck KGaA, Darmstadt, GermanySep 30, 202043
NCT03693170Colorectal Neoplasms · United States, Austria, Belgium and more2CompletedPierre FabreJun 29, 202095
NCT03391934Colorectal Neoplasms · Iran, Islamic Republic of3RecruitingcinnagenNov 30, 2025234
NCT03362684Colorectal Neoplasms3Completedintegragen-saNov 20091,808
NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more3CompletedBristol-Myers SquibbOct 14, 201974
NCT02643550Head and Neck Neoplasms · United States, France2Completedinnate-pharmaMar 28, 2023143
NCT02383966Squamous Cell Carcinoma of Head and Neck · Germany3CompletedMerck KGaA, Darmstadt, GermanyJan 19, 2018243
NCT02350712Squamous Cell Carcinoma of Head and Neck · United Kingdom1CompletedDaiichi SankyoMar 201615
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedHoffmann-La RocheMay 31, 20191,044
NCT02124850Squamous Cell Carcinoma of Head and Neck · United States1TerminatedBristol-Myers SquibbAug 11, 201618
NCT02020577Neoplasms · France, Spain1CompletedBoehringer IngelheimJan 201558
NCT01973868Neoplasms · United States1CompletedBayerJan 31, 201742
NCT01719380Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedPfizerOct 31, 2015156
NCT01602315Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada and more2TerminatedNovartisSep 16, 2016179
NCT01451632Colorectal Neoplasms · United States1CompletedMerrimack PharmaceuticalsNov 201348
NCT01450319Colorectal Neoplasms · Spain2CompletedMerck KGaA, Darmstadt, GermanyDec 201473
NCT01388790Stomach Neoplasms · Germany2CompletedMerck KGaA, Darmstadt, GermanyAug 201240
NCT01252628Recurrence · United States, Canada2CompletedPfizerNov 2013178
NCT01228734Colorectal Neoplasms · China3CompletedMerck KGaA, Darmstadt, GermanyJan 25, 2016553
NCT01177956Squamous Cell Carcinoma of Head and Neck · China, Korea, Republic of3CompletedMerck KGaA, Darmstadt, GermanyJan 201173
NCT01109524Lung Neoplasms · United States, Canada, Puerto Rico2CompletedEli LillySep 201272
NCT01099358Head and Neck Neoplasms · United States, Canada2CompletedEli LillyOct 201547
NCT01087970Head and Neck Neoplasms · United States2CompletedEli LillyAug 201369
NCT01086267Colorectal Neoplasms · United States, Canada2CompletedBristol-Myers SquibbAug 201117
NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico2CompletedEli LillyAug 2013187
NCT01063075Head and Neck Neoplasms · United States, Canada2CompletedEli LillyMay 201534
NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more2CompletedEli LillyFeb 201266
NCT01012258Squamous Cell Carcinoma of Head and Neck · China3CompletedMerck KGaA, Darmstadt, GermanySep 201070
NCT00971932Squamous Cell Carcinoma of Head and Neck · Japan2CompletedMerck KGaA, Darmstadt, GermanyMar 201133
NCT00927147Head and Neck Neoplasms · Finland2Terminatedboneca-corporationJun 201317
NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more2CompletedEli LillyMay 2011113
NCT00865098Carcinoma of the Head and Neck · Japan2CompletedMerck KGaA, Darmstadt, GermanyJun 201027
NCT00820755Carcinoma, Non-Small-Cell Lung · Germany3CompletedMerck KGaA, Darmstadt, GermanyDec 2011583
NCT00820417Colorectal Neoplasms · Belgium, Spain1Completedharrison-clinical-researchSep 200763
NCT00768131Lung Neoplasms · United States2WithdrawnEli LillyOct 20080
NCT00698841Advanced Cancer · United States, Puerto Rico2CompletedEli LillyFeb 201079
NCT00678535Stomach Neoplasms · Argentina, Australia, Austria and more3CompletedMerck KGaA, Darmstadt, GermanyMar 2012904
NCT00633464Breast Neoplasms · Austria, Czech Republic, France and more2CompletedR-PharmSep 201079
NCT00594984Colorectal Neoplasms · United States, Argentina, Denmark and more2CompletedBristol-Myers SquibbDec 201238
NCT00577109Colorectal Neoplasms · Brazil2WithdrawnHoffmann-La RocheJun 20120
NCT00540943Colorectal Neoplasms · France1CompletedGlaxoSmithKlineMay 3, 201025
NCT00527111Rectal Neoplasms · United States2CompletedSarah Cannon Research InstituteJan 2015139
NCT00517829Gastric Cancer Adenocarcinoma Metastatic · United States2CompletedSarah Cannon Research InstituteApr 2012150
NCT00497497Colorectal Neoplasms1CompletedHoffmann-La RocheSep 201020

How it is read

Names in the registry

  • “Cetuximab”, 57 entries
  • “cetuximab”, 11 entries
  • “RPH-002”, 2 entries
  • “Cetuximab + Irinotecan”, 2 entries
  • “Cetuximab + mFOLFOX6”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.